Medicines (Nasdaq: MDCO ) reported earnings on Oct. 24. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Medicines met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded and GAAP earnings per share shrank significantly.
Gross margins grew, operating margins increased, net margins shrank.
Medicines booked revenue of $136.8 million. The five analysts polled by S&P Capital IQ wanted to see sales of $136.5 million on the same basis. GAAP reported sales were 13% higher than the prior-year quarter's $120.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.40. The four earnings estimates compiled by S&P Capital IQ predicted $0.39 per share. GAAP EPS of $0.17 for Q3 were 87% lower than the prior-year quarter's $1.34 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 68.0%, 70 basis points better than the prior-year quarter. Operating margin was 11.0%, 150 basis points better than the prior-year quarter. Net margin was 6.8%, 5,330 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $146.5 million. On the bottom line, the average EPS estimate is $0.42.
Next year's average estimate for revenue is $546.2 million. The average EPS estimate is $1.40.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 131 members out of 145 rating the stock outperform, and 14 members rating it underperform. Among 28 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 27 give Medicines a green thumbs-up, and one give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Medicines is outperform, with an average price target of $27.40.
- Add Medicines to My Watchlist.